Stock Track | IDEXX Laboratories Soars 5.31% in Pre-Market on Q2 Earnings Release Anticipation

Stock Track

Aug 04

IDEXX Laboratories' stock surged 5.31% in pre-market trading, as investors reacted positively to the company's release of its second fiscal quarter earnings report before the market open. The market is anticipating an adjusted earnings per share of $3.95 for the quarter.

In the previous quarter, IDEXX reported revenue of $1.141 billion, surpassing the consensus estimate of $1.109 billion, though adjusted EPS of $3.30 slightly missed the $3.40 estimate. Despite the EPS miss, the company raised its full-year guidance, citing improved clinical visit volumes and higher diagnostic frequency at veterinary practices. IDEXX has also recently expanded its Fecal Dx antigen testing platform with tapeworm detection capabilities and launched a Cancer Dx Panel for early detection of canine lymphoma in the UK, broadening its diagnostic coverage. Analyst consensus maintains an overweight rating with a mean price target of $713.46, well above current levels.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1101885022"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1101885022\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1101885022?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-04 18:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1101885022","market":"sg","top_or_hot":-1,"title":"Stock Track | IDEXX Laboratories Soars 5.31% in Pre-Market on Q2 Earnings Release Anticipation","media":"Stock Track","content":"<p>IDEXX Laboratories' stock surged 5.31% in pre-market trading, as investors reacted positively to the company's release of its second fiscal quarter earnings report before the market open. The market is anticipating an adjusted earnings per share of $3.95 for the quarter.</p>\n<p>In the previous quarter, IDEXX reported revenue of $1.141 billion, surpassing the consensus estimate of $1.109 billion, though adjusted EPS of $3.30 slightly missed the $3.40 estimate. Despite the EPS miss, the company raised its full-year guidance, citing improved clinical visit volumes and higher diagnostic frequency at veterinary practices. IDEXX has also recently expanded its Fecal Dx antigen testing platform with tapeworm detection capabilities and launched a Cancer Dx Panel for early detection of canine lymphoma in the UK, broadening its diagnostic coverage. Analyst consensus maintains an overweight rating with a mean price target of $713.46, well above current levels.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | IDEXX Laboratories Soars 5.31% in Pre-Market on Q2 Earnings Release Anticipation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | IDEXX Laboratories Soars 5.31% in Pre-Market on Q2 Earnings Release Anticipation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-08-04 18:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>IDEXX Laboratories' stock surged 5.31% in pre-market trading, as investors reacted positively to the company's release of its second fiscal quarter earnings report before the market open. The market is anticipating an adjusted earnings per share of $3.95 for the quarter.</p>\n<p>In the previous quarter, IDEXX reported revenue of $1.141 billion, surpassing the consensus estimate of $1.109 billion, though adjusted EPS of $3.30 slightly missed the $3.40 estimate. Despite the EPS miss, the company raised its full-year guidance, citing improved clinical visit volumes and higher diagnostic frequency at veterinary practices. IDEXX has also recently expanded its Fecal Dx antigen testing platform with tapeworm detection capabilities and launched a Cancer Dx Panel for early detection of canine lymphoma in the UK, broadening its diagnostic coverage. Analyst consensus maintains an overweight rating with a mean price target of $713.46, well above current levels.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IDXX","symbol_name":"爱德士实验室","start_time":0,"source_url":"","article_id":"1101885022","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1101885022","pubTimestamp":1785838944,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"IDEXX Laboratories' stock surged 5.31% in pre-market trading, as investors reacted positively to the company's release of its second fiscal quarter earnings report before the market open. The market...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IDXX":"爱德士实验室"},"translate_title":"股票跟踪 | IDEXX Laboratories 因第二季度财报发布预期在盘前飙升 5.31%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IDXX":1},"content_text":"IDEXX Laboratories' stock surged 5.31% in pre-market trading, as investors reacted positively to the company's release of its second fiscal quarter earnings report before the market open. The market is anticipating an adjusted earnings per share of $3.95 for the quarter.\nIn the previous quarter, IDEXX reported revenue of $1.141 billion, surpassing the consensus estimate of $1.109 billion, though adjusted EPS of $3.30 slightly missed the $3.40 estimate. Despite the EPS miss, the company raised its full-year guidance, citing improved clinical visit volumes and higher diagnostic frequency at veterinary practices. IDEXX has also recently expanded its Fecal Dx antigen testing platform with tapeworm detection capabilities and launched a Cancer Dx Panel for early detection of canine lymphoma in the UK, broadening its diagnostic coverage. Analyst consensus maintains an overweight rating with a mean price target of $713.46, well above current levels.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}